（一）募集资金的基本情况 的核查意见 中国银河证券股份有限公司（以下简称"银河证券"或"保荐人"）作为汕头市 超声仪器研究所股份有限公司（以下简称"公司"或"超研股份"）首次公开发行股 票并上市的保荐人，根据《中华人民共和国公司法》《中华人民共和国证券法》《证 券发行上市保荐业务管理办法（2023 修订）》《上市公司监管指引第 2 号——上市公 司募集资金管理和使用的监管要求（2022 年修订）》《深圳证券交易所创业板股票上 市规则（2024 年修订）》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作（2023 年 12 月修订）》等有关规定，对超研股份调整募投项目内 部结构、实施进度及超募资金使用计划的事项进行了审慎核查，发表核查意见如下： 一、募集资金概况 中国银河证券股份有限公司 关于汕头市超声仪器研究所股份有限公司 调整募投项目内部结构、实施进度及超募资金使用计划 经中国证券监督管理委员会《关于同意汕头市超声仪器研究所股份有限公司首次 公开发行股票注册的批复》（证监许可〔2024〕1391 号）同意注册，公司已完成首次 公开发行人民币普通股（A 股）64,249,446 股， ...

汕头市超声仪器研究所股份有限公司 内部控制审计报告 华兴审字[2025]25004170033 号 华兴会计师事务所(特殊普通合伙) 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.eov.cn）"进行查 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.eov.cn）"进行至5 5 计师事务所(特殊普通合 CERTIFIED PUBLIC ACCOL 内部控制审计报告 华兴审字[2025]25004170033号 汕头市超声仪器研究所股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求, 我们审计了汕头市超声仪器研究所股份有限公司（以下简称"超研股份"） 2024年12月31日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业 内部控制评价指引》的规定,建立健全和有效实施内部控制,并评价其有效 性是超研股份董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性 发表审计意见,并对注意到的非 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥98,432,423.04, representing a 28.69% increase compared to ¥76,490,637.69 in the same period last year[4] - Net profit attributable to shareholders for Q1 2025 was ¥39,321,956.98, up 47.70% from ¥26,623,641.96 in the previous year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥36,958,544.46, reflecting a 58.78% increase from ¥23,276,483.10 year-over-year[8] - Basic and diluted earnings per share for Q1 2025 were both ¥0.10, representing a 42.86% increase from ¥0.07 in the same period last year[8] - Total operating revenue for the current period reached ¥98,432,423.04, an increase of 28.7% compared to ¥76,490,637.69 in the previous period[20] - Net profit for the current period was ¥39,321,956.98, representing a significant increase of 47.8% from ¥26,623,641.96 in the previous period[21] - Basic and diluted earnings per share improved to ¥0.10 from ¥0.07, reflecting a growth of 42.9%[22] Cash Flow and Liquidity - The net cash flow from operating activities was ¥38,039,030.13, a 53.69% increase compared to ¥24,750,149.18 in the same period last year[4] - Operating cash inflow for the current period reached $125,931,740.21, a significant increase from $86,704,603.35 in the previous period, representing a growth of approximately 45.2%[24] - Net cash flow from operating activities amounted to $38,039,030.13, up from $24,750,149.18, indicating a year-over-year increase of about 53.4%[25] - The net increase in cash and cash equivalents for the period was $412,920,478.03, compared to $17,115,295.83 in the previous period, showing a substantial increase[25] - The ending balance of cash and cash equivalents reached $615,399,581.57, significantly higher than $111,656,417.50 at the end of the previous period[25] - The company reported cash receipts from operating activities, including tax refunds of $5,496,002.09, which is a notable increase from $1,130,548.50[24] Assets and Liabilities - Total assets at the end of Q1 2025 reached ¥1,412,092,153.94, a 40.36% increase from ¥1,006,037,837.71 at the end of the previous year[4] - Total current assets increased to 1,292,025,161.15 RMB from 879,665,743.61 RMB, representing a growth of approximately 47%[16] - The total assets increased to ¥1,412,092,153.94 from ¥1,006,037,837.71, marking a growth of 40.4%[18] - The total liabilities decreased to ¥118,511,582.72 from ¥135,377,063.86, a reduction of 12.4%[18] Shareholder Information - Shareholders' equity attributable to the company was ¥1,293,580,571.22, up 48.57% from ¥870,660,773.85 at the end of the previous year[4] - The largest shareholder, Shantou Ultrasonic Asset Management Co., holds 51.32% of shares, totaling 219,830,247 shares[10] - The second largest shareholder, Shantou Municipal Government State-owned Assets Supervision and Administration Commission, holds 31.14% of shares, totaling 133,369,945 shares[10] - Total number of common shareholders at the end of the reporting period is 26,755[10] Expenses and Costs - Total operating costs amounted to ¥57,345,176.36, up from ¥50,601,040.15, reflecting a growth of 13.4%[20] - The company experienced a 34.17% increase in management expenses, totaling ¥9,444,052.87, primarily due to increased consulting and meeting costs[7] - Research and development expenses for the current period were ¥11,476,627.29, compared to ¥10,391,176.86 in the previous period, indicating a rise of 10.4%[20] Cash and Investment Activities - Cash inflow from investment activities totaled $634,041,047.55, compared to $397,976,180.06 in the prior period, reflecting a growth of approximately 59.2%[25] - Cash outflow from investment activities was $646,329,625.52, which is an increase from $405,639,488.18, resulting in a net cash flow from investment activities of -$12,288,577.97[25] - Cash inflow from financing activities was $401,633,651.91, with cash outflow totaling $14,404,923.00, leading to a net cash flow from financing activities of $387,228,728.91[25] - The company received $632,276,812.55 in cash from investment recoveries, up from $395,183,873.76, marking an increase of approximately 60%[25] Other Information - The company received government subsidies amounting to ¥583,185.04, which are closely related to its normal business operations[5] - The company has no changes in the number of restricted shares for major shareholders during the reporting period[13] - The total number of restricted shares remains at 364,080,192, with no shares released during the period[14] - The company has not disclosed any new product developments or market expansion strategies in the current report[15] - The cash flow statement will provide insights into the company's liquidity and operational efficiency, with further details to be disclosed[23] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[22]

Dividend Distribution - The company plans to distribute a cash dividend of 1.02 RMB per 10 shares (including tax) to all shareholders[4]. - The company will not issue any bonus shares as part of the profit distribution plan[4]. - The board of directors has approved the profit distribution plan during the meeting[4]. - The cash dividend amount accounts for 100% of the total profit distribution, with no other forms of cash distribution such as share buybacks[191]. - The cash dividend policy aligns with the company's articles of association and shareholder meeting resolutions, ensuring transparency and compliance[191]. - The cash dividend distribution is based on the actual operational needs and long-term development plans of the company[192]. Financial Performance - The company's operating revenue for 2024 reached ¥375,813,223.81, representing a 15.09% increase compared to ¥326,542,857.93 in 2023[20]. - Net profit attributable to shareholders for 2024 was ¥145,577,556.51, a 26.12% increase from ¥115,427,511.56 in 2023[20]. - The net profit after deducting non-recurring gains and losses was ¥136,263,774.66, up 33.09% from ¥102,381,917.91 in 2023[20]. - Cash flow from operating activities for 2024 was ¥132,394,299.90, an increase of 80.33% compared to ¥73,416,726.11 in 2023[20]. - Basic earnings per share for 2024 were ¥0.40, a 25.00% increase from ¥0.32 in 2023[20]. - Total assets at the end of 2024 amounted to ¥1,006,037,837.71, reflecting a 19.85% increase from ¥839,422,579.64 at the end of 2023[20]. - Net assets attributable to shareholders increased by 20.30% to ¥870,660,773.85 at the end of 2024 from ¥723,766,407.95 at the end of 2023[20]. - The company reported a quarterly revenue of ¥114,642,683.53 in Q4 2024, showing consistent growth throughout the year[22]. Risk Management - The report emphasizes the importance of understanding the risks associated with future plans and strategies[4]. - The company has outlined potential risk factors and countermeasures in the management discussion section[4]. - The company faces risks from industry regulations and policy changes, particularly in the medical device sector, which could impact market access and financial performance[129]. - Currency exchange rate fluctuations pose a risk to the company's overseas revenue, which is primarily settled in USD and EUR, potentially affecting sales and profit margins[130]. - International trade tensions, such as US-China trade friction, may introduce uncertainties in overseas markets, affecting business expansion and supply chain stability[131]. Research and Development - The company has established multiple R&D centers, including in Shantou, Xi'an, Guangzhou, and Seattle, focusing on advanced imaging technologies and cloud-based software systems[43]. - The R&D team comprises 115 personnel, representing 15.21% of total employees, with core technical staff accounting for 10.43% of the R&D team[46]. - R&D expenses accounted for 13.32% of total revenue, maintaining a stable level above 10% for several consecutive years[51]. - The company is developing a portable low-radiation artificial intelligence DR imaging diagnostic system to enhance diagnostic efficiency and product competitiveness, with prototype testing and software design in progress[69]. - The company is focusing on the application and expansion of multimodal products in the emergency rescue field, enhancing features such as vital signs monitoring and AI-assisted diagnosis[125]. Product Development and Market Expansion - The company is a pioneer in the domestic ultrasound diagnosis and testing industry, with significant advancements in various technologies such as color Doppler ultrasound imaging systems and industrial ultrasonic testing instruments[31]. - The medical ultrasound imaging equipment market is expanding, driven by smart and innovative technologies, with a focus on portable devices and AI integration[29]. - The company aims to deepen domestic market penetration while expanding into emerging markets along the Belt and Road Initiative[29]. - The company has developed a portable DR device with a built-in high-capacity battery, marking a significant innovation in the industry[34]. - The company is actively pursuing regulatory approvals for new products, with several registrations in 2023, indicating a proactive approach to market expansion[95]. Governance and Compliance - The company has established a robust information disclosure management system to enhance transparency and protect shareholder rights[142]. - The company's governance practices align with legal and regulatory standards, with no significant discrepancies identified[144]. - The company has established an independent financial department with a complete accounting system, ensuring no shared bank accounts with the controlling shareholder[146]. - The company has a complete and independent asset structure, with no reliance on the controlling shareholder's assets for operations[145]. - The company has maintained effective internal controls without any major deficiencies affecting the evaluation conclusion during the reporting period[196]. Employee Management - The total number of employees at the end of the reporting period is 756, with 669 from the parent company and 87 from major subsidiaries[186]. - The company has established a comprehensive employee compensation and benefits management system to enhance employee satisfaction and loyalty[187]. - Training programs are aligned with the company's development strategy, focusing on enhancing management and key personnel's strategic analysis and management capabilities[188]. - The company is committed to enhancing its human resources planning and incentive mechanisms to attract and retain top talent[135]. Financial Strategy - The company plans to invest approximately 240 million CNY in new fixed and intangible assets, leading to an annual increase in depreciation and amortization of about 40 million CNY[133]. - The company will continue to support distributors through training, technical support, and marketing activities to ensure sustained sales revenue growth[133]. - The company has no significant equity investments or securities investments during the reporting period, indicating a conservative investment strategy[114]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million yuan allocated for potential deals[174].

超研股份（301602）公告，公司于2025年4月27日召开的第二届董事会第八次会议上，审议通过了向全 资子公司深圳汕超增资的议案。公司计划以自有资金人民币50万元增资深圳汕超。增资完成后，深圳汕 超的注册资本将由人民币50万元增加至人民币100万元，仍为公司全资子公司。本次增资旨在支持深圳 汕超的业务发展，不涉及关联交易或重大资产重组，不需提交股东会审议。增资预计不会对公司财务状 况和经营成果产生重大影响。 ...

一、本次增资事项概述 汕头市超声仪器研究所股份有限公司（以下简称"公司"）于2025 年4月27日召开第二届董事会第八次会议，审议通过了《关于向子公 司增资的议案》，根据公司的发展战略和全资子公司深圳市汕超科技 有限公司（以下简称"深圳汕超"）的经营管理需要，公司拟以自有 资金人民币50万元对深圳汕超进行增资。本次增资完成后，深圳汕超 的注册资本由人民币50万元增加至人民币100万元，仍为公司全资子 公司。 根据《深圳证券交易所创业板股票上市规则（2024 年修订）》和 《公司章程》等相关规定，本次对外投资在公司董事会审议权限内， 无需提交公司股东会审议。本次对外投资不构成关联交易，也不构成 《上市公司重大资产重组管理办法》规定的重大资产重组。 二、增资标的基本情况 1、公司名称：深圳市汕超科技有限公司 证券代码：301602 证券简称：超研股份 公告编号：2025-018 汕头市超声仪器研究所股份有限公司 关于向子公司增资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 2、成立日期：2015年10月26日 3、注册地址：深圳市福田区梅林街道中康路12 ...

证券代码：301602 证券简称：超研股份 公告编号：2025-009 汕头市超声仪器研究所股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 3、类型：股份有限公司（上市） 4、法定代表人：李德来 5、注册资本：人民币 428,329,638 元 一、工商变更登记情况 汕头市超声仪器研究所股份有限公司（以下简称"公司"）于 2025 年 2 月 13 日召开第二届董事会第七次会议审议通过了《关于修 订上市后适用的〈公司章程〉并提交工商备案的议案》《关于因上市 变更公司注册资本、公司类型并办理工商变更登记的议案》，并于 2025 年 3 月 3 日召开 2025 年第一次临时股东会审议通过上述两项议 案，具体内容详见公司于巨潮资讯网（http://www.cninfo.com.cn） 披露的相关公告。 近日，公司就上述事项办理完成工商变更登记手续及《公司章程》 备案手续，取得了汕头市市场监督管理局核发的《营业执照》，现将 新取得《营业执照》的基本信息公告如下： 1、统一社会信用代码：9144050045594 ...

医药生物行业 增持（首次） 国内超声诊断和检测行业的先行者 分析师：谢雄雄 SAC 执业证书编号： S0340523110002 电话：0769-22110925 邮箱： xiexiongxiong@dgzq.com.cn | 主要数据 2025 年 3 月 | 19 | 日 | | --- | --- | --- | | 收盘价（元） 27.15 | | | | 总市值（亿元） 116.29 | | | | 总股本（亿股） 4.28 | | | | 流通股本（亿股）0.55 | | | | ROE(TTM) 15.16% | | | | 12 月最高价（元）32.10 | | | | 12 月最低价（元）21.60 | | | 股价走势 资料来源：东莞证券研究所，iFind 相关报告 投资要点： ◼ 风险提示。新产品的市场开拓风险、原材料采购风险、行业监管及政 策变化风险和国际贸易摩擦风险等。 超研股份（301602）深度报告 2025 年 3 月 20 日 公 本报告的风险等级为中高风险。 本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。 请务必阅读末页声明 ...

北 京 上 海 深 圳 杭 州 广 州 昆 明 天 津 成 都 宁 波 福 州 西 安 南 京 南 宁 济 南 重 庆 苏 州 长 沙 太 原 武 汉 贵 阳 乌鲁木齐 郑 州 石家庄 合 肥 海 南 青 岛 南 昌 香 港 巴 黎 马德里 斯德哥尔摩 纽 约 广州市天河区华夏路 32 号太平洋金融大厦 19 楼 邮编：510620 电话：(+86)(20) 3879 9346 、38799348 传真：(+86)(20) 3879 9348-200 国浩律师(广州)事务所 关于汕头市超声仪器研究所股份有限公司 2025 年第一次临时股东会的法律意见 汕头市超声仪器研究所股份有限公司： 根据中国证券监督管理委员会发布的《上市公司股东大会规则》(以下简称 《股东大会规则》)的要求，国浩律师(广州)事务所(以下简称"本所")接受汕 头市超声仪器研究所股份有限公司(以下简称"超研股份")的委托，指派程秉、 周姗姗律师(以下简称"本所律师")出席超研股份 2025 年第一次临时股东会(以 下简称"本次股东会")，对本次股东会的召集与召开程序、出席会议人员与召 集人的资格、表决程序与表决结果等重要事项出具法律意见。 本 ...

证券代码：301602 证券简称：超研股份 公告编号：2025-008 汕头市超声仪器研究所股份有限公司 2025年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形； 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一） 召开情况 1、会议召开时间： （1）现场会议：2025年3月3日（星期一）下午15:00 （2）网络投票：通过深圳证券交易所交易系统进行网络投票的 时间为2025年3月3日上午9:15-9:25，9:30-11:30，下午13:00-15:00； 通过深圳证券交易所互联网系统投票的具体时间为2025年3月3日 9:15-15:00期间的任意时间。 2、现场会议召开地点：广东省汕头市金砂路77号汕头市超声仪 器研究所股份有限公司101会议室 3、召开方式：本次股东会采取现场投票与网络投票相结合的表 决方式。 4、召集人：汕头市超声仪器研究所股份有限公司董事会 5、主持人：董事长李德来先生 6、会议的召开符合相关法律、行政法规、部门规章、规范性文 ...